Figure 2. Anti-rhGAA IgG1 and IgG4 are the most prevalent subclasses of antibodies developed in response to long-term ERT.

(A–F) Anti-rhGAA antibodies measured with a capture assay specific for IgG1, IgG2, IgG3, IgG4, IgM, and IgE antibodies. Estimated antibody concentrations are reported for each subject. Average and standard deviation are indicated for each of the study cohorts: LOPD subjects receiving ERT (Treated, n = 28), untreated LOPD subjects (Untreated, n = 10), and healthy donors (HD, n = 43). Unpaired two-tailed t-test was used to compare results across the study cohorts (**P < 0.01).